Literature DB >> 18253773

[Chemotherapy for brain tumors in adult patients].

M Weller1.   

Abstract

Chemotherapy has become a third major treatment option for patients with brain tumors, in addition to surgery and radiotherapy. The role of chemotherapy in the treatment of gliomas is no longer limited to recurrent disease. Temozolomide has become the standard of care in newly diagnosed glioblastoma. Several ongoing trials seek to define the role of chemotherapy in the primary care of other gliomas. Some of these studies are no longer only based on histological diagnoses, but take into consideration molecular markers such as MGMT promoter methylation and loss of genetic material on chromosomal arms 1p and 19q. Outside such clinical trials chemotherapy is used in addition to radiotherapy, e.g., in anaplastic astrocytoma, medulloblastoma or germ cell tumors, or as an alternative to radiotherapy, e.g., in anaplastic oligodendroglial tumors or low-grade gliomas. In contrast, there is no established role for chemotherapy in other tumors such as ependymomas, meningiomas or neurinomas. Primary cerebral lymphomas are probably the only brain tumors which can be cured by chemotherapy alone and only by chemotherapy. The chemotherapy of brain metastases follows the recommendations for the respective primary tumors. Further, strategies of combined radiochemotherapy using mainly temozolomide or topotecan are currently explored. Leptomeningeal metastases are treated by radiotherapy or systemic or intrathecal chemotherapy depending on their pattern of growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18253773     DOI: 10.1007/s00115-007-2372-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  16 in total

1.  Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse.

Authors:  Ulrich Herrlinger; A Steinbrecher; J Rieger; P Hau; R-D Kortmann; R Meyermann; M Schabet; M Bamberg; J Dichgans; U Bogdahn; M Weller
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

2.  A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia.

Authors:  Alba A Brandes; Giovanna Cavallo; Michele Reni; Alicia Tosoni; Linda Nicolardi; Luciano Scopece; Enrico Franceschi; Guido Sotti; Andrea Talacchi; Sergio Turazzi; Mario Ermani
Journal:  Cancer       Date:  2005-07-01       Impact factor: 6.860

Review 3.  Neoplastic meningitis.

Authors:  Marc C Chamberlain
Journal:  Neurologist       Date:  2006-07       Impact factor: 1.398

4.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

Authors:  Gregory Cairncross; Brian Berkey; Edward Shaw; Robert Jenkins; Bernd Scheithauer; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperierre; Minesh Mehta; Walter Curran
Journal:  J Clin Oncol       Date:  2006-06-20       Impact factor: 44.544

5.  Combined chemotherapy and radiotherapy for intracranial germinomas in adult patients: a single-institution study.

Authors:  Antonio Silvani; Marica Eoli; Andrea Salmaggi; Elena Lamperti; Laura Fariselli; Ida Milanesi; Giovanni Broggi; Carlo Lazzaro Solero; Sergio Giombini; Amerigo Boiardi
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

6.  Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

Authors:  Michael Weller; Bettina Müller; Rainer Koch; Michael Bamberg; Peter Krauseneck
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

7.  Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

Authors:  Antje Wick; Jörg Felsberg; Joachim P Steinbach; Ulrich Herrlinger; Michael Platten; Britta Blaschke; Richard Meyermann; Guido Reifenberger; Michael Weller; Wolfgang Wick
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

8.  [Neurooncology].

Authors:  M Weller
Journal:  Nervenarzt       Date:  2003-12       Impact factor: 1.214

Review 9.  Malignant pineal parenchymal tumors in adult patients: patterns of care and prognostic factors.

Authors:  Johannes Lutterbach; François Fauchon; Steven E Schild; Susan M Chang; Axel Pagenstecher; Benedikt Volk; Christoph Ostertag; Felix Momm; Anne Jouvet
Journal:  Neurosurgery       Date:  2002-07       Impact factor: 4.654

10.  Primary central nervous system lymphoma.

Authors:  Hendrik Pels; Uwe Schlegel
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972

View more
  1 in total

1.  Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study.

Authors:  Marco Ronald Hassler; Wolfgang Pfeifer; Thomas Hendrik Knocke-Abulesz; Klaus Geissler; Gabriele Altorjai; Karin Dieckmann; Christine Marosi
Journal:  Wien Klin Wochenschr       Date:  2013-08-02       Impact factor: 1.704

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.